Holen Sie sich die Stockscreener-App
15.43
1.92%
0.29
Handel nachbörslich:
15.45
0.02
+0.13%
Schlusskurs vom Vortag:
$15.14
Offen:
$14.76
24-Stunden-Volumen:
1.90M
Relative Volume:
1.06
Marktkapitalisierung:
$1.57B
Einnahmen:
$52.60M
Nettoeinkommen (Verlust:
$-485.50M
KGV:
-2.826
EPS:
-5.46
Netto-Cashflow:
$-418.08M
1W Leistung:
+2.94%
1M Leistung:
-14.23%
6M Leistung:
-34.62%
1J Leistung:
-46.35%
1-Tages-Spanne:
$14.55
$15.44
1-Wochen-Bereich:
$13.95
$15.44
52-Wochen-Spanne:
$13.95
$34.87
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Data UnderwhelmsIntellia's Cash, Data And Competition Are A Challenging Story - Seeking Alpha
This Beaten-Down Stock Could Soar by 354%, According to Wall Street - Yahoo Finance
(NTLA) Long Term Investment Analysis - Stock Traders Daily
Capital Advisors Inc. OK Has $4.19 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
NTLAIntellia Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024 - GlobeNewswire
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study - MSN
Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies - Insider Monkey
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
In the wake of Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest US$619m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Reasons For Intellia Therapeutics Stock Plunge Are Flimsy, But Don't Buck Mr. Market - Seeking Alpha
Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 5.8%What's Next? - MarketBeat
Oversold Conditions For Intellia Therapeutics (NTLA) - Nasdaq
Intellia Therapeutics Advances with Promising Phase 2 Results - Yahoo Finance
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy - MSN
Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity (NTLA) - Seeking Alpha
Intellia Therapeutics price target lowered to $65 from $80 at BofA - MSN
Intellia reports positive data from Phase II study of NTLA-2002 for HAE - Clinical Trials Arena
7 Analysts Have This To Say About Intellia Therapeutics - Benzinga
Intellia’s CRISPR Gene Editor Cuts Hereditary Angioedema Attacks by 81% in Phase II Study - BioSpace
Robert W. Baird Trims Intellia Therapeutics (NASDAQ:NTLA) Target Price to $18.00 - MarketBeat
Phase II Intellia data fail to impress investors - The Pharma Letter
Intellia trumpets CRISPR drug data, but shares fall - pharmaphorum
MNPR,NTLA,CPRI,WDC,TSLA: Top 5 Trending Stocks TodayMonopar Therapeutics (NASDAQ:MNPR), Capri Holdings (NYSE:CPRI) - Benzinga
Intellia's CRISPR drug slashes HAE attacks, but investor doubts persist - FirstWord Pharma
Why Intellia Therapeutics Stock Plummeted by 20% Today - sharewise
Why Intellia Therapeutics (NTLA) Stock Dropped Today - GuruFocus.com
Intellia Therapeutics (NASDAQ:NTLA) Given New $88.00 Price Target at Chardan Capital - MarketBeat
A Closer Look at Intellia Therapeutics's Options Market Dynamics - Benzinga
Intellia stock touches 52-week low at $16.86 amid market shifts By Investing.com - Investing.com South Africa
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday? - Benzinga
3 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release - Yahoo Finance
Intellia retains outperform stock rating amid trial results - Investing.com
Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Fo - GuruFocus.com
Intellia data spark debate about CRISPR drug’s potential - BioPharma Dive
Baird cuts Intellia stock target, neutral rating on gene editing concerns - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year LowShould You Sell? - MarketBeat
Intellia stock touches 52-week low at $16.86 amid market shifts - Investing.com
Intellia reports promising Phase 2 results for HAE treatment By Investing.com - Investing.com South Africa
Intellia stock slips after gene editing data (NTLA:NASDAQ) - Seeking Alpha
Intellia reports promising Phase 2 results for HAE treatment - Investing.com
CRISPR-Based Therapy for Hereditary Angioedema - nejm.org
Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) - StockTitan
Intellia Moves Into Phase III With NTLA-2002, But Concerns Remain - Citeline
2 Biotech Stocks Making Big Moves - Schaeffers Research
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '24 |
Sale |
22.93 |
405 |
9,287 |
71,470 |
| Verwiel Frank | Director |
Jun 17 '24 |
Sale |
25.00 |
1,505 |
37,625 |
17,948 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '24 |
Sale |
32.99 |
2,297 |
75,778 |
81,571 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '24 |
Sale |
32.99 |
605 |
19,959 |
71,470 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 08 '24 |
Sale |
28.87 |
2,275 |
65,682 |
43,927 |
| LEONARD JOHN M | President and CEO |
Jan 03 '24 |
Sale |
29.46 |
19,223 |
566,310 |
846,486 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '24 |
Sale |
29.46 |
5,843 |
172,135 |
54,372 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '24 |
Sale |
29.46 |
5,532 |
162,973 |
46,202 |
| Goddard Glenn | EVP, Chief Financial Officer |
Jan 03 '24 |
Sale |
29.46 |
5,365 |
158,053 |
40,585 |
| Hicks Derek | EVP, Chief Business Officer |
Jan 03 '24 |
Sale |
29.46 |
3,877 |
114,216 |
36,987 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):